Histidine

Histidine

SCHEMBL1673287

NC(CS)C(=O)O.NC(Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.48
SLC7A11 Q9UPY5 1/20 0.48
SLC7A5 Q01650 3/20 0.42
CYP3A4 P08684 2/20 0.42
CYP1A2 P05177 1/20 0.41
PKM P14618 2/20 0.38
ALPI P09923 1/20 0.38
XIAP P98170 1/20 0.38
GRIA2 P42262 4/20 0.36
GRIA1 P42261 3/20 0.36
GRIA3 P42263 3/20 0.36
GRIA4 P48058 3/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
BLM P54132 2/20 0.35
PMP22 Q01453 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL18047802 1.00 PTGS1 (0.48) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL851432 1.00 PTGS1 (0.48) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL22091426 1.00 PTGS1 (0.48) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL27769589 1.00 PTGS1 (0.48) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL4452747 1.00 PTGS1 (0.48) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL28655326 0.98 PTGS1 (0.47) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL28511880 0.98 PTGS1 (0.47) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL28203991 0.98 PTGS1 (0.47) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL1692193 0.98 PTGS1 (0.47) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2
Histidine SCHEMBL1257407 0.94 PTGS1 (0.43) PTGS1SLC7A11SLC7A5CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114558029-A Copper cluster, thymine modified hyaluronic acid and poly-copper cluster, and preparation method and application thereof 武汉广行科学研究有限公司 2022-05-31 CN claimed
CN-109939243-A Copper cluster, thymine modified hyaluronic acid and poly-copper cluster, and preparation method and application thereof 深圳广行科学研究有限公司 2019-06-28 CN claimed
CN-109022381-A Amino acid dehydrogenase mutant and its application 凯莱英生命科学技术(天津)有限公司 2018-12-18 CN claimed
WO-2003099322-A2 IL-11 DERIVATIVES AND THERAPEUTIC USES THEREOF ISIS INNOVATION LIMITED (GB) 2003-12-04 WO claimed
EP-0829206-A1 Edible micro-emulsion for coating food products and its use for browning and crisping in a microwave SOCIETE DES PRODUITS NESTLE S.A. (CH) 1998-03-18 EP claimed
EP-0769549-A2 Enzyme mutants having a low degree of variation of the molecular charge over a pH range NOVO NORDISK A/S (DK) 1997-04-23 EP claimed
WO-1992011357-A1 ENZYME MUTANTS HAVING A LOW DEGREE OF VARIATION OF THE MOLECULAR CHARGE OVER A pH RANGE NOVO NORDISK A/S (DK) 1992-07-09 WO claimed
US-20240238443-A1 Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating Glaucoma Shenzhen Profound-View Pharma Tech Co., Ltd (CN) 2024-07-18 US disclosed
WO-2024117904-A1 RECEPTOR- AND DRUG-DEPENDENT REGULATED ON-SITE PRODUCTION OF BIOLOGICALS Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) 2024-06-06 WO disclosed
EP-4372090-A2 CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS Editas Medicine, Inc. (US) 2024-05-22 EP disclosed
CN-114940713-B Anti-TRKB antibodies 清华大学 2024-04-30 CN disclosed
US-11969477-B2 Application of AuCs or substances containing AuCs in the preparation of drugs for preventing and/or treating glaucoma Shenzhen Profound-View Pharma Tech Co., Ltd (CN) 2024-04-30 US disclosed
US-20240132916-A1 NUCLEASE-GUIDED NON-LTR RETROTRANSPOSONS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2024-04-25 US disclosed
EP-0787186-A1 NEURONAL APOPTOSIS INHIBITOR PROTEIN, GENE SEQUENCE AND MUTATIONS CAUSATIVE OF SPINAL MUSCULAR ATROPHY UNIVERSITY OF OTTAWA (CA) 1997-08-06 EP disclosed
EP-0769549-A2 Enzyme mutants having a low degree of variation of the molecular charge over a pH range NOVO NORDISK A/S (DK) 1997-04-23 EP disclosed
WO-1996012016-A1 NEURONAL APOPTOSIS INHIBITOR PROTEIN, GENE SEQUENCE AND MUTATIONS CAUSATIVE OF SPINAL MUSCULAR ATROPHY THE UNIVERSITY OF OTTAWA (CA) 1996-04-25 WO disclosed
WO-1994023030-A2 METHODS AND MATERIALS RELATING TO THE FUNCTIONAL DOMAINS OF DNA BINDING PROTEINS ARCH DEVELOPMENT CORPORATION (US) 1994-10-13 WO disclosed
EP-0563103-A1 ENZYMES AND ENZYMATIC DETERGENT COMPOSITIONS UNILEVER PLC (GB) 1993-10-06 EP disclosed
WO-1992011357-A1 ENZYME MUTANTS HAVING A LOW DEGREE OF VARIATION OF THE MOLECULAR CHARGE OVER A pH RANGE NOVO NORDISK A/S (DK) 1992-07-09 WO disclosed
WO-1992011348-A1 ENZYMES AND ENZYMATIC DETERGENT COMPOSITIONS UNILEVER N.V. (NL) 1992-07-09 WO disclosed